Presentation and Real-World Management of ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Presentation and Real-World Management of Giant Cell Arteritis (Artemis Study).
Auteur(s) :
Mahr, A. [Auteur]
Service de Médecine Interne [Saint-Louis]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
De Boysson, H. [Auteur]
Service de médecine interne [CHU Caen]
Guerroui, N. [Auteur]
Hôpital Européen [Fondation Ambroise Paré - Marseille]
Héron, E. [Auteur]
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts [CHNO]
Vinzio, S. [Auteur]
Groupe Hospitalier Mutualiste [Grenoble] [GHM]
Broner, J. [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Lapébie, F. X. [Auteur]
Service Médecine interne [CHU Toulouse]
Michaud, M. [Auteur]
Hôpital Joseph Ducuing - Varsovie [Toulouse] [HJD]
Sailler, L. [Auteur]
Zenone, T. [Auteur]
Centre hospitalier de Valence
Djerad, M. [Auteur]
Médecine interne et infectiologie [CH Pierre Bérégovoy - Nevers]
Jouvray, M. [Auteur]
Groupe Hospitalier Artois-Ternois Centre Hospitalier d’Arras
Shipley, E. [Auteur]
Centre Hospitalier de Dax
Tieulie, N. [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Armengol, G. [Auteur]
Service de Médecine Interne [CHU Rouen]
Bouldoires, B. [Auteur]
Hôpitaux Civils de Colmar
Viallard, J. F. [Auteur]
Service de médecine interne et maladies infectieuses [Bordeaux]
Idier, I. [Auteur]
Paccalin, M. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Devauchelle-Pensec, V. [Auteur]
Service de Rhumatologie [CHU de la Cavale-Blanche]
Hôpital de la Cavale Blanche - CHRU Brest [CHU - BREST ]
Service de Médecine Interne [Saint-Louis]
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
De Boysson, H. [Auteur]
Service de médecine interne [CHU Caen]
Guerroui, N. [Auteur]
Hôpital Européen [Fondation Ambroise Paré - Marseille]
Héron, E. [Auteur]
Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts [CHNO]
Vinzio, S. [Auteur]
Groupe Hospitalier Mutualiste [Grenoble] [GHM]
Broner, J. [Auteur]
Centre Hospitalier Universitaire de Nîmes [CHU Nîmes]
Lapébie, F. X. [Auteur]
Service Médecine interne [CHU Toulouse]
Michaud, M. [Auteur]
Hôpital Joseph Ducuing - Varsovie [Toulouse] [HJD]
Sailler, L. [Auteur]
Zenone, T. [Auteur]
Centre hospitalier de Valence
Djerad, M. [Auteur]
Médecine interne et infectiologie [CH Pierre Bérégovoy - Nevers]
Jouvray, M. [Auteur]
Groupe Hospitalier Artois-Ternois Centre Hospitalier d’Arras
Shipley, E. [Auteur]
Centre Hospitalier de Dax
Tieulie, N. [Auteur]
Centre Hospitalier Universitaire de Nice [CHU Nice]
Armengol, G. [Auteur]
Service de Médecine Interne [CHU Rouen]
Bouldoires, B. [Auteur]
Hôpitaux Civils de Colmar
Viallard, J. F. [Auteur]
Service de médecine interne et maladies infectieuses [Bordeaux]
Idier, I. [Auteur]
Paccalin, M. [Auteur]
Centre hospitalier universitaire de Poitiers = Poitiers University Hospital [CHU de Poitiers [La Milétrie]]
Devauchelle-Pensec, V. [Auteur]
Service de Rhumatologie [CHU de la Cavale-Blanche]
Hôpital de la Cavale Blanche - CHRU Brest [CHU - BREST ]
Titre de la revue :
Frontiers in Medicine
Nom court de la revue :
Front Med (Lausanne)
Numéro :
8
Pagination :
732934
Date de publication :
2021-12-07
ISSN :
2296-858X
Mot(s)-clé(s) en anglais :
giant cell arteritis
phenotype [mesh]
management
healthcare
observational
glucocorticoids (GCs)
methotrexate
tocilizumab
phenotype [mesh]
management
healthcare
observational
glucocorticoids (GCs)
methotrexate
tocilizumab
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Background: Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting.
Methods: ...
Lire la suite >Background: Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting. Methods: Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment. Patient characteristics and journey, diagnostic methods and treatments were collected. Descriptive analyses were performed. Results: In total, 306 patients (67% females, mean age 74 ± 8 years old) were recruited by 69 physicians (internists: 85%, rheumatologists: 15%); 13% of patients had newly diagnosed GCA (diagnosis-to-visit interval <6 weeks). Overall median disease duration was 13 months (interquartile range 5–26). Most patients were referred by general practitioners (56%), then ophthalmologists (10%) and neurologists (7%). Most common comorbidities were hypertension (46%), psychiatric disorders (10%), dyslipidemia (12%), diabetes (9%), and osteoporosis (6%). Initial GCA presentations included cranial symptoms (89%), constitutional symptoms (74%), polymyalgia rheumatica (48%), and/or other extra-cranial manifestations (35%). Overall, 85, 31, 26, and 30% of patients underwent temporal artery biopsy, high-resolution temporal artery Doppler ultrasonography, 18FDG-PET, and aortic angio-CT, respectively. All patients received glucocorticoids, which were ongoing for 89%; 29% also received adjunct medication(s) (methotrexate: 19%, tocilizumab: 15%). A total of 40% had relapse(s); the median time to the first relapse was 10 months. Also, 37% had comorbidity(ies) related to or aggravated by glucocorticoids therapy. Conclusion: This large observational study provides insight into current medical practices for GCA. More than one third of patients had comorbidities related to glucocorticoid therapy for a median disease duration of 13 months. Methotrexate and tocilizumab were the most common adjunct medications.Lire moins >
Lire la suite >Background: Few studies of daily practice for patients with giant cell arteritis (GCA) are available. This French study aimed to describe the characteristics and management of GCA in a real-life setting. Methods: Cross-sectional, non-interventional, multicenter study of patients ≥50 years old who consulted hospital-based specialists for GCA and were under treatment. Patient characteristics and journey, diagnostic methods and treatments were collected. Descriptive analyses were performed. Results: In total, 306 patients (67% females, mean age 74 ± 8 years old) were recruited by 69 physicians (internists: 85%, rheumatologists: 15%); 13% of patients had newly diagnosed GCA (diagnosis-to-visit interval <6 weeks). Overall median disease duration was 13 months (interquartile range 5–26). Most patients were referred by general practitioners (56%), then ophthalmologists (10%) and neurologists (7%). Most common comorbidities were hypertension (46%), psychiatric disorders (10%), dyslipidemia (12%), diabetes (9%), and osteoporosis (6%). Initial GCA presentations included cranial symptoms (89%), constitutional symptoms (74%), polymyalgia rheumatica (48%), and/or other extra-cranial manifestations (35%). Overall, 85, 31, 26, and 30% of patients underwent temporal artery biopsy, high-resolution temporal artery Doppler ultrasonography, 18FDG-PET, and aortic angio-CT, respectively. All patients received glucocorticoids, which were ongoing for 89%; 29% also received adjunct medication(s) (methotrexate: 19%, tocilizumab: 15%). A total of 40% had relapse(s); the median time to the first relapse was 10 months. Also, 37% had comorbidity(ies) related to or aggravated by glucocorticoids therapy. Conclusion: This large observational study provides insight into current medical practices for GCA. More than one third of patients had comorbidities related to glucocorticoid therapy for a median disease duration of 13 months. Methotrexate and tocilizumab were the most common adjunct medications.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
Inserm
CHU Lille
Inserm
CHU Lille
Date de dépôt :
2024-01-12T05:32:35Z
2024-02-27T09:25:56Z
2024-05-22T12:24:09Z
2024-02-27T09:25:56Z
2024-05-22T12:24:09Z
Fichiers
- fmed-08-732934 (1).pdf
- Version éditeur
- Accès libre
- Accéder au document